Checkpoint Therapeutics Other Current Liabilities

Checkpoint Therapeutics's other current liabilities stands at $18M as of March 2025. That compares with $7.4M in the prior-year period — up 142.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Checkpoint Therapeutics reported $18M in other current liabilities versus $7.4M a year earlier — a 142.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $7.4M in the prior-year period — up 142.8% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Checkpoint Therapeutics's other current liabilities evolved across reporting periods, while the comparison chart places CKPT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. Checkpoint Therapeutics's reading of $18M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.